Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 22.
doi: 10.1113/JP289449. Online ahead of print.

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity

S Jeromson  1   2 , B Baranowski  1   2 , M Akcan  1 , B D Waters  1 , K Eisner  1 , A Bellucci  1 , S Trang  1 , A Abolhassani  3 , M A Tello-Palencia  3 , A Schweitzer  1 , B Stefanska  3 , C J Mitchell  1 , David C Wright  1   2   3
Affiliations

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity

S Jeromson et al. J Physiol. .

Abstract

Semaglutide is a GLP-1 receptor agonist that is highly efficacious in reducing food intake and body weight. While semaglutide reduces adipose tissue, there is also a loss of lean mass including skeletal muscle, though it is unclear whether this translates to a loss of muscle function. The effect of discontinuation of semaglutide on rebound weight gain and shifts in body composition is also not well understood. We investigated the impact of semaglutide and matched caloric restriction on body composition in mice with diet-induced obesity. Mice were treated with semaglutide or fed a calorie-matched diet for 4 weeks. Semaglutide and pair-feeding induced significant weight loss with a concomitant reduction in energy expenditure. Weight loss was greater with semaglutide than caloric restriction, despite matched energy intake. Muscle transcriptomic analyses revealed distinct molecular responses between semaglutide and pair-feeding. In a follow-up experiment, semaglutide and pair-feeding was discontinued after 4 weeks, and body weight and food intake were tracked for 6 weeks. At the end of the withdrawal period there was a loss of treatment effects. Lean and fat mass rebounded to baseline levels at the end of the withdrawal period. Muscle size and strength were also comparable between groups. These findings demonstrate that semaglutide reduces muscle size and strength to the same extent as caloric restriction but may be more effective at promoting fat loss. Interestingly, the loss of lean mass and skeletal muscle recovered following treatment discontinuation. KEY POINTS: Semaglutide results in greater weight loss than caloric restriction. Semaglutide treatment increases fat loss compared with caloric restriction. Muscle mass and strength is reduced to a similar extent by semaglutide and restricted feeding.

Keywords: obesity; semaglutide; skeletal muscle; weight loss.

PubMed Disclaimer

References

    1. Arbeau, M., Baranowski, B. J., Jeromson, S., Bellucci, A., Akcan, M., Trang, S., Eisner, K., Medak, K. D., & Wright, D. C. (2024). GDF15 associates with, but is not responsible for, exercise‐induced increases in corticosterone and indices of lipid utilization in mice. Journal of Applied Physiology (1985), 137(6), 1512–1523.
    1. Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., … Fitzgibbons, W. (2019). PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, 42(9), 1724–1732.
    1. Blomain, E. S., Dirhan, D. A., Valentino, M. A., Kim, G. W., & Waldman, S. A. (2013). Mechanisms of weight regain following weight loss. International Scholarly Research Network Obesity, 2013, 210524.
    1. Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism, 19(9), 1242–1251.
    1. Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.‐M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z.‐Q., Valenzuela, D. M., Dechiara, T. M., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001). Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294(5547), 1704–1708.

LinkOut - more resources